Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| WEST PHARMACEUTICAL SERVICES INCWST · Entity 3201 | VP Strat & Investor Relations | February 20, 2024 | February 22, 2024 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
WEST PHARMACEUTICAL SERVICES INC
Report date February 20, 2024 · Filed February 22, 2024
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 4,358.784 |
Reported balance
After 2024-02-20 transaction · row 1
Account or security details depend on footnotes; rows are not merged.
1 source rowRow 1 · 2024-02-20 · Grant · Acquired 375 · Balance 4,358.784 F1: 2021 PSUs (PP20) award vesting net of taxes withheld. |
Filing footnotes · ownership attribution and instrument terms
F1: 2021 PSUs (PP20) award vesting net of taxes withheld.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| February 20, 2024 Filed Feb 22, 2024 23:22 UTC | WEST PHARMACEUTICAL SERVICES INC WST · Entity 3201 | GrantCommon Stock | 375 | $0.00 | $0.00 |
DisclosureSEC source: 0001127602-24-006392 · form4.xml · nonDerivative · entry 1 Lai Quintin J · CIK 0001744326 · VP Strat & Investor Relations 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 4,358.784 F1 · security: 2021 PSUs (PP20) award vesting net of taxes withheld. Read SEC document |
| August 11, 2023 Filed Aug 15, 2023 18:50 UTC | WEST PHARMACEUTICAL SERVICES INC WST · Entity 3201 | Exercise / conversionStock Options (Right to buy) · Derivative | 453 | $0.00 Strike: $369.13 | $0.00 |
DisclosureSEC source: 0001562180-23-006338 · primarydocument.xml · derivative · entry 13 Lai Quintin J · CIK 0001744326 · VP Strat & Investor Relations 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 1,359 Underlying: Common Stock · 453 shares Expires 2032-02-22 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F7 · derivative.exercise_date: This award vests in four equal annual installments beginning on February 22, 2023. Read SEC document |
| August 11, 2023 Filed Aug 15, 2023 18:50 UTC | WEST PHARMACEUTICAL SERVICES INC WST · Entity 3201 | Exercise / conversionStock Options (Right to buy) · Derivative | 1,388 | $0.00 Strike: $274.29 | $0.00 |
DisclosureSEC source: 0001562180-23-006338 · primarydocument.xml · derivative · entry 12 Lai Quintin J · CIK 0001744326 · VP Strat & Investor Relations 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 1,388 Underlying: Common Stock · 1,388 shares Expires 2031-02-23 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F6 · derivative.exercise_date: This award vests in 4 equal annual installments beginning on 2/23/2022. Read SEC document |
| August 11, 2023 Filed Aug 15, 2023 18:50 UTC | WEST PHARMACEUTICAL SERVICES INC WST · Entity 3201 | Exercise / conversionStock Options (Right to Buy) · Derivative | 3,348 | $0.00 Strike: $173.22 | $0.00 |
DisclosureSEC source: 0001562180-23-006338 · primarydocument.xml · derivative · entry 11 Lai Quintin J · CIK 0001744326 · VP Strat & Investor Relations 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 1,116 Underlying: Common Stock · 3,348 shares Expires 2030-02-18 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F5 · derivative.exercise_date: This award vests in four equal annual installments beginning on February 18, 2021. Read SEC document |
| August 11, 2023 Filed Aug 15, 2023 18:50 UTC | WEST PHARMACEUTICAL SERVICES INC WST · Entity 3201 | Exercise / conversionStock Options (Right to buy) · Derivative | 7,140 | $0.00 Strike: $102.51 | $0.00 |
DisclosureSEC source: 0001562180-23-006338 · primarydocument.xml · derivative · entry 10 Lai Quintin J · CIK 0001744326 · VP Strat & Investor Relations 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 7,140 shares Expires 2029-02-19 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F4 · derivative.exercise_date: This option is fully vested. Read SEC document |
| August 11, 2023 Filed Aug 15, 2023 18:50 UTC | WEST PHARMACEUTICAL SERVICES INC WST · Entity 3201 | Exercise / conversionStock Option (Right to Buy) · Derivative | 8,772 | $0.00 Strike: $89.64 | $0.00 |
DisclosureSEC source: 0001562180-23-006338 · primarydocument.xml · derivative · entry 9 Lai Quintin J · CIK 0001744326 · VP Strat & Investor Relations 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 8,772 shares Expires 2028-02-20 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F4 · derivative.exercise_date: This option is fully vested. Read SEC document |
| August 11, 2023 Filed Aug 15, 2023 18:50 UTC | WEST PHARMACEUTICAL SERVICES INC WST · Entity 3201 | SaleCommon Stock | 1,741 | $396.12 | $689,650.14 |
DisclosureSEC source: 0001562180-23-006338 · primarydocument.xml · nonDerivative · entry 8 Lai Quintin J · CIK 0001744326 · VP Strat & Investor Relations 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 18,306.93 F3 · price: The price reported in Column 4 is an average price. These shares were purchased in multiple transactions at prices ranging from $395.97 to $396.45, inclusive. The reporting person undertakes to provide to West Pharmaceutical Services, Inc., any security holder of West Pharmaceutical Services, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range in this footnote. Read SEC document |
| August 11, 2023 Filed Aug 15, 2023 18:50 UTC | WEST PHARMACEUTICAL SERVICES INC WST · Entity 3201 | SaleCommon Stock | 8,635 | $395.54 | $3,415,510.35 |
DisclosureSEC source: 0001562180-23-006338 · primarydocument.xml · nonDerivative · entry 7 Lai Quintin J · CIK 0001744326 · VP Strat & Investor Relations 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 20,047.93 F2 · price: The price reported in Column 4 is an average price. These shares were purchased in multiple transactions at prices ranging from $394.97 to $395.93, inclusive. The reporting person undertakes to provide to West Pharmaceutical Services, Inc., any security holder of West Pharmaceutical Services, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range in this footnote. Read SEC document |
| August 11, 2023 Filed Aug 15, 2023 18:50 UTC | WEST PHARMACEUTICAL SERVICES INC WST · Entity 3201 | SaleCommon Stock | 10,725 | $394.62 | $4,232,326.31 |
DisclosureSEC source: 0001562180-23-006338 · primarydocument.xml · nonDerivative · entry 6 Lai Quintin J · CIK 0001744326 · VP Strat & Investor Relations 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 28,682.93 F1 · price: The price reported in Column 4 is an average price. These shares were purchased in multiple transactions at prices ranging from $393.97 to $394.96, inclusive. The reporting person undertakes to provide to West Pharmaceutical Services, Inc., any security holder of West Pharmaceutical Services, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range in this footnote. Read SEC document |
| August 11, 2023 Filed Aug 15, 2023 18:50 UTC | WEST PHARMACEUTICAL SERVICES INC WST · Entity 3201 | Exercise / conversionCommon Stock | 453 | $369.13 | $167,215.89 |
DisclosureSEC source: 0001562180-23-006338 · primarydocument.xml · nonDerivative · entry 5 Lai Quintin J · CIK 0001744326 · VP Strat & Investor Relations 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 39,407.93 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| August 11, 2023 Filed Aug 15, 2023 18:50 UTC | WEST PHARMACEUTICAL SERVICES INC WST · Entity 3201 | Exercise / conversionCommon Stock | 1,388 | $274.29 | $380,714.52 |
DisclosureSEC source: 0001562180-23-006338 · primarydocument.xml · nonDerivative · entry 4 Lai Quintin J · CIK 0001744326 · VP Strat & Investor Relations 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 38,954.93 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| August 11, 2023 Filed Aug 15, 2023 18:50 UTC | WEST PHARMACEUTICAL SERVICES INC WST · Entity 3201 | Exercise / conversionCommon Stock | 3,348 | $173.22 | $579,940.56 |
DisclosureSEC source: 0001562180-23-006338 · primarydocument.xml · nonDerivative · entry 3 Lai Quintin J · CIK 0001744326 · VP Strat & Investor Relations 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 37,566.93 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| August 11, 2023 Filed Aug 15, 2023 18:50 UTC | WEST PHARMACEUTICAL SERVICES INC WST · Entity 3201 | Exercise / conversionCommon Stock | 7,140 | $102.51 | $731,921.40 |
DisclosureSEC source: 0001562180-23-006338 · primarydocument.xml · nonDerivative · entry 2 Lai Quintin J · CIK 0001744326 · VP Strat & Investor Relations 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 34,218.93 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| August 11, 2023 Filed Aug 15, 2023 18:50 UTC | WEST PHARMACEUTICAL SERVICES INC WST · Entity 3201 | Exercise / conversionCommon Stock | 8,772 | $89.64 | $786,322.08 |
DisclosureSEC source: 0001562180-23-006338 · primarydocument.xml · nonDerivative · entry 1 Lai Quintin J · CIK 0001744326 · VP Strat & Investor Relations 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 27,078.93 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| February 21, 2023 Filed Feb 23, 2023 23:30 UTC | WEST PHARMACEUTICAL SERVICES INC WST · Entity 3201 | GrantStock Options (Right to buy) · Derivative | 1,724 | $0.00 Strike: $306.68 | $0.00 |
DisclosureSEC source: 0001562180-23-001800 · primarydocument.xml · derivative · entry 2 Lai Quintin J · CIK 0001744326 · VP Corp Development & Strategy 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,724 Underlying: Stock Options (Right to Buy) · 1,724 shares Expires 2033-02-21 F2 · derivative.exercise_date: This award vests in four equal annual installments beginning on February 21, 2024. Read SEC document |
| February 21, 2023 Filed Feb 23, 2023 23:30 UTC | WEST PHARMACEUTICAL SERVICES INC WST · Entity 3201 | GrantCommon Stock | 1,134 | $306.68 | $347,775.12 |
DisclosureSEC source: 0001562180-23-001800 · primarydocument.xml · nonDerivative · entry 1 Lai Quintin J · CIK 0001744326 · VP Corp Development & Strategy 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 18,306.93 F1 · shares: 2020 PSUs (PP19) award vesting net of taxes withheld Read SEC document |
| March 14, 2022 Filed Mar 16, 2022 15:16 UTC | WEST PHARMACEUTICAL SERVICES INC WST · Entity 3201 | Exercise / conversionStock Options (Right to buy) · Derivative | 5,576 | $0.00 Strike: $83.47 | $0.00 |
DisclosureSEC source: 0001562180-22-002665 · primarydocument.xml · derivative · entry 12 Lai Quintin J · CIK 0001744326 · VP Corp Development & Strategy 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 29,064 Underlying: Common Stock · 5,576 shares Expires 2027-02-21 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| March 14, 2022 Filed Mar 16, 2022 15:16 UTC | WEST PHARMACEUTICAL SERVICES INC WST · Entity 3201 | Exercise / conversionStock Options (Right to buy) · Derivative | 2,440 | $0.00 Strike: $94.27 | $0.00 |
DisclosureSEC source: 0001562180-22-002665 · primarydocument.xml · derivative · entry 11 Lai Quintin J · CIK 0001744326 · VP Corp Development & Strategy 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 34,640 Underlying: Common Stock · 2,440 shares Expires 2027-02-05 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| March 14, 2022 Filed Mar 16, 2022 15:16 UTC | WEST PHARMACEUTICAL SERVICES INC WST · Entity 3201 | SaleCommon Stock | 200 | $374.92 | $74,984.00 |
DisclosureSEC source: 0001562180-22-002665 · primarydocument.xml · nonDerivative · entry 10 Lai Quintin J · CIK 0001744326 · VP Corp Development & Strategy 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 5,371.8424 Read SEC document |
| March 14, 2022 Filed Mar 16, 2022 15:16 UTC | WEST PHARMACEUTICAL SERVICES INC WST · Entity 3201 | SaleCommon Stock | 2,940 | $374.45 | $1,100,880.65 |
DisclosureSEC source: 0001562180-22-002665 · primarydocument.xml · nonDerivative · entry 9 Lai Quintin J · CIK 0001744326 · VP Corp Development & Strategy 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 5,571.8424 F7 · price: The price reported in Column 4 is an average price. These shares were purchased in multiple transactions at prices ranging from $373.86 to $374.83, inclusive. The reporting person undertakes to provide to West Pharmaceutical Services, Inc., any security holder of West Pharmaceutical Services, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range in this footnote. Read SEC document |
| March 14, 2022 Filed Mar 16, 2022 15:16 UTC | WEST PHARMACEUTICAL SERVICES INC WST · Entity 3201 | SaleCommon Stock | 900 | $372.92 | $335,631.60 |
DisclosureSEC source: 0001562180-22-002665 · primarydocument.xml · nonDerivative · entry 8 Lai Quintin J · CIK 0001744326 · VP Corp Development & Strategy 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 8,511.8424 F6 · price: The price reported in Column 4 is an average price. These shares were purchased in multiple transactions at prices ranging from $372.70 to $373.46, inclusive. The reporting person undertakes to provide to West Pharmaceutical Services, Inc., any security holder of West Pharmaceutical Services, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range in this footnote. Read SEC document |
| March 14, 2022 Filed Mar 16, 2022 15:16 UTC | WEST PHARMACEUTICAL SERVICES INC WST · Entity 3201 | SaleCommon Stock | 600 | $371.89 | $223,132.20 |
DisclosureSEC source: 0001562180-22-002665 · primarydocument.xml · nonDerivative · entry 7 Lai Quintin J · CIK 0001744326 · VP Corp Development & Strategy 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 9,411.8424 F5 · price: The price reported in Column 4 is an average price. These shares were purchased in multiple transactions at prices ranging from $371.65 to $372.40, inclusive. The reporting person undertakes to provide to West Pharmaceutical Services, Inc., any security holder of West Pharmaceutical Services, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range in this footnote. Read SEC document |
| March 14, 2022 Filed Mar 16, 2022 15:16 UTC | WEST PHARMACEUTICAL SERVICES INC WST · Entity 3201 | SaleCommon Stock | 446 | $370.94 | $165,440.62 |
DisclosureSEC source: 0001562180-22-002665 · primarydocument.xml · nonDerivative · entry 6 Lai Quintin J · CIK 0001744326 · VP Corp Development & Strategy 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 10,011.8424 F4 · price: The price reported in Column 4 is an average price. These shares were purchased in multiple transactions at prices ranging from $370.41 to $371.32, inclusive. The reporting person undertakes to provide to West Pharmaceutical Services, Inc., any security holder of West Pharmaceutical Services, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range in this footnote. Read SEC document |
| March 14, 2022 Filed Mar 16, 2022 15:16 UTC | WEST PHARMACEUTICAL SERVICES INC WST · Entity 3201 | SaleCommon Stock | 1,254 | $369.86 | $463,801.31 |
DisclosureSEC source: 0001562180-22-002665 · primarydocument.xml · nonDerivative · entry 5 Lai Quintin J · CIK 0001744326 · VP Corp Development & Strategy 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 10,457.8424 F3 · price: The price reported in Column 4 is an average price. These shares were purchased in multiple transactions at prices ranging from $369.40 to $370.36, inclusive. The reporting person undertakes to provide to West Pharmaceutical Services, Inc., any security holder of West Pharmaceutical Services, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range in this footnote. Read SEC document |
| March 14, 2022 Filed Mar 16, 2022 15:16 UTC | WEST PHARMACEUTICAL SERVICES INC WST · Entity 3201 | SaleCommon Stock | 405 | $367.94 | $149,017.40 |
DisclosureSEC source: 0001562180-22-002665 · primarydocument.xml · nonDerivative · entry 4 Lai Quintin J · CIK 0001744326 · VP Corp Development & Strategy 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 11,711.8424 F2 · price: The price reported in Column 4 is an average price. These shares were purchased in multiple transactions at prices ranging from $367.56 to $368.22, inclusive. The reporting person undertakes to provide to West Pharmaceutical Services, Inc., any security holder of West Pharmaceutical Services, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range in this footnote. Read SEC document |
| March 14, 2022 Filed Mar 16, 2022 15:16 UTC | WEST PHARMACEUTICAL SERVICES INC WST · Entity 3201 | SaleCommon Stock | 1,271 | $367.12 | $466,603.93 |
DisclosureSEC source: 0001562180-22-002665 · primarydocument.xml · nonDerivative · entry 3 Lai Quintin J · CIK 0001744326 · VP Corp Development & Strategy 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 12,116.8424 F1 · price: The price reported in Column 4 is an average price. These shares were purchased in multiple transactions at prices ranging from $366.50 to $367.42, inclusive. The reporting person undertakes to provide to West Pharmaceutical Services, Inc., any security holder of West Pharmaceutical Services, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range in this footnote. Read SEC document |
| March 14, 2022 Filed Mar 16, 2022 15:16 UTC | WEST PHARMACEUTICAL SERVICES INC WST · Entity 3201 | Exercise / conversionCommon Stock | 5,576 | $83.47 | $465,428.72 |
DisclosureSEC source: 0001562180-22-002665 · primarydocument.xml · nonDerivative · entry 2 Lai Quintin J · CIK 0001744326 · VP Corp Development & Strategy 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 13,387.8424 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| March 14, 2022 Filed Mar 16, 2022 15:16 UTC | WEST PHARMACEUTICAL SERVICES INC WST · Entity 3201 | Exercise / conversionCommon Stock | 2,440 | $94.27 | $230,018.80 |
DisclosureSEC source: 0001562180-22-002665 · primarydocument.xml · nonDerivative · entry 1 Lai Quintin J · CIK 0001744326 · VP Corp Development & Strategy 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 7,811.8424 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| February 22, 2022 Filed Feb 25, 2022 02:23 UTC | WEST PHARMACEUTICAL SERVICES INC WST · Entity 3201 | GrantCommon Stock | 3,138 | $369.13 | $1,158,329.94 |
DisclosureSEC source: 0001562180-22-001905 · primarydocument.xml · nonDerivative · entry 1 Lai Quintin J · CIK 0001744326 · VP Corp Development & Strategy 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 5,371.8424 F1 · shares: 2019 PSUs (PP18) award vesting net of taxes withheld. The net shares were deferred as deferred stock units in the Non-Qualified Deferred Compensation (NQDC) plan for employees to be distributed in accordance with the terms of the NQDC plan and their individual elections Read SEC document |
| February 22, 2022 Filed Feb 24, 2022 21:55 UTC | WEST PHARMACEUTICAL SERVICES INC WST · Entity 3201 | GrantStock Options (Right to buy) · Derivative | 1,812 | $0.00 Strike: $369.13 | $0.00 |
DisclosureSEC source: 0001562180-22-001884 · primarydocument.xml · derivative · entry 1 Lai Quintin J · CIK 0001744326 · VP Corp Development & Strategy 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,812 Underlying: Stock Options (Right to Buy) · 1,812 shares Expires 2032-02-22 F1 · derivative.exercise_date: This award vests in four equal annual installments beginning on February 22, 2023. Read SEC document |
| September 10, 2021 Filed Sep 14, 2021 14:45 UTC | WEST PHARMACEUTICAL SERVICES INC WST · Entity 3201 | Exercise / conversionStock Option (Right to Buy) · Derivative | 1,000 | $0.00 Strike: $72.97 | $0.00 |
DisclosureSEC source: 0001562180-21-005939 · primarydocument.xml · derivative · entry 7 Lai Quintin J · CIK 0001744326 · VP Corp Development & Strategy 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 1,000 shares Expires 2026-10-18 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| September 10, 2021 Filed Sep 14, 2021 14:45 UTC | WEST PHARMACEUTICAL SERVICES INC WST · Entity 3201 | Exercise / conversionStock Option (Right to Buy) · Derivative | 8,672 | $0.00 Strike: $59.64 | $0.00 |
DisclosureSEC source: 0001562180-21-005939 · primarydocument.xml · derivative · entry 6 Lai Quintin J · CIK 0001744326 · VP Corp Development & Strategy 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 8,672 shares Expires 2026-02-23 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| September 10, 2021 Filed Sep 14, 2021 14:45 UTC | WEST PHARMACEUTICAL SERVICES INC WST · Entity 3201 | SaleCommon Stock | 1,500 | $462.63 | $693,945.90 |
DisclosureSEC source: 0001562180-21-005939 · primarydocument.xml · nonDerivative · entry 5 Lai Quintin J · CIK 0001744326 · VP Corp Development & Strategy 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,233.8424 F3 · price: The price reported in Column 4 is an average price. These shares were purchased in multiple transactions at prices ranging from $462.48 to $462.805, inclusive. The reporting person undertakes to provide to West Pharmaceutical Services, Inc., any security holder of West Pharmaceutical Services, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range in this footnote. Read SEC document |
| September 10, 2021 Filed Sep 14, 2021 14:45 UTC | WEST PHARMACEUTICAL SERVICES INC WST · Entity 3201 | SaleCommon Stock | 3,100 | $460.80 | $1,428,493.95 |
DisclosureSEC source: 0001562180-21-005939 · primarydocument.xml · nonDerivative · entry 4 Lai Quintin J · CIK 0001744326 · VP Corp Development & Strategy 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 3,733.8424 F2 · price: The price reported in Column 4 is an average price. These shares were purchased in multiple transactions at prices ranging from $460.50 to $461.44, inclusive. The reporting person undertakes to provide to West Pharmaceutical Services, Inc., any security holder of West Pharmaceutical Services, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range in this footnote. Read SEC document |
| September 10, 2021 Filed Sep 14, 2021 14:45 UTC | WEST PHARMACEUTICAL SERVICES INC WST · Entity 3201 | SaleCommon Stock | 5,072 | $460.18 | $2,334,011.66 |
DisclosureSEC source: 0001562180-21-005939 · primarydocument.xml · nonDerivative · entry 3 Lai Quintin J · CIK 0001744326 · VP Corp Development & Strategy 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 6,833.8424 F1 · price: The price reported in Column 4 is an average price. These shares were purchased in multiple transactions at prices ranging from $459.50 to $460.44, inclusive. The reporting person undertakes to provide to West Pharmaceutical Services, Inc., any security holder of West Pharmaceutical Services, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range in this footnote. Read SEC document |
| September 10, 2021 Filed Sep 14, 2021 14:45 UTC | WEST PHARMACEUTICAL SERVICES INC WST · Entity 3201 | Exercise / conversionCommon Stock | 1,000 | $72.97 | $72,970.00 |
DisclosureSEC source: 0001562180-21-005939 · primarydocument.xml · nonDerivative · entry 2 Lai Quintin J · CIK 0001744326 · VP Corp Development & Strategy 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 11,905.8424 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| September 10, 2021 Filed Sep 14, 2021 14:45 UTC | WEST PHARMACEUTICAL SERVICES INC WST · Entity 3201 | Exercise / conversionCommon Stock | 8,672 | $59.64 | $517,198.08 |
DisclosureSEC source: 0001562180-21-005939 · primarydocument.xml · nonDerivative · entry 1 Lai Quintin J · CIK 0001744326 · VP Corp Development & Strategy 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 10,905.8424 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| February 23, 2021 Filed Feb 25, 2021 22:45 UTC | WEST PHARMACEUTICAL SERVICES INC WST · Entity 3201 | GrantStock Options (Right to buy) · Derivative | 2,776 | $0.00 Strike: $274.29 | $0.00 |
DisclosureSEC source: 0001562180-21-001592 · primarydocument.xml · derivative · entry 1 Lai Quintin J · CIK 0001744326 · VP Corp Development & Strategy 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,776 Underlying: Common Stock · 2,776 shares Expires 2031-02-23 F1 · derivative.exercise_date: This award vests in 4 equal annual installments beginning on 2/23/2022. Read SEC document |
| February 22, 2021 Filed Feb 24, 2021 22:34 UTC | WEST PHARMACEUTICAL SERVICES INC WST · Entity 3201 | GrantCommon Stock | 2,936 | $272.65 | $800,500.40 |
DisclosureSEC source: 0001562180-21-001575 · primarydocument.xml · nonDerivative · entry 1 Lai Quintin J · CIK 0001744326 · VP Corp Development & Strategy 10b5-1 filing: Not disclosed Ownership: Indirect · Non-Qualified Deferred Compensation Plan Disclosed balance after: 2,936 F1 · shares: 2018 PSUs (PP17) award vesting net of taxes withheld. Read SEC document |
| February 18, 2020 Filed Feb 21, 2020 01:07 UTC | WEST PHARMACEUTICAL SERVICES INC WST · Entity 3201 | GrantStock Options (Right to Buy) · Derivative | 4,464 | $0.00 Strike: $173.22 | $0.00 |
DisclosureSEC source: 0001562180-20-001425 · primarydocument.xml · derivative · entry 2 Lai Quintin J · CIK 0001744326 · VP Corp Development & Strategy 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 4,464 Underlying: Common Stock · 4,464 shares Expires 2030-02-18 F2 · derivative.exercise_date: This award vests in four equal annual installments beginning on February 18, 2021. Read SEC document |
| February 18, 2020 Filed Feb 21, 2020 01:07 UTC | WEST PHARMACEUTICAL SERVICES INC WST · Entity 3201 | GrantCommon Stock | 1,013 | $173.22 | $175,471.86 |
DisclosureSEC source: 0001562180-20-001425 · primarydocument.xml · nonDerivative · entry 1 Lai Quintin J · CIK 0001744326 · VP Corp Development & Strategy 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,233.8424 F1 · shares: 2017 PSUs (PP16) award vesting. Read SEC document |
| February 19, 2019 Filed Feb 21, 2019 23:07 UTC | WEST PHARMACEUTICAL SERVICES INC WST · Entity 3201 | GrantStock Options (Right to buy) · Derivative | 7,140 | $102.51 Strike: $102.51 | $731,921.40 |
DisclosureSEC source: 0001562180-19-001179 · primarydocument.xml · derivative · entry 2 Lai Quintin J · CIK 0001744326 · VP Corp Development & Strategy 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 7,140 Underlying: Common Stock · 7,140 shares Expires 2029-02-19 F2 · derivative.exercise_date: This award vests in four equal annual installments beginning on February 19, 2020. Read SEC document |
| February 19, 2019 Filed Feb 21, 2019 23:07 UTC | WEST PHARMACEUTICAL SERVICES INC WST · Entity 3201 | GrantCommon Stock | 561 | $102.51 | $57,508.11 |
DisclosureSEC source: 0001562180-19-001179 · primarydocument.xml · nonDerivative · entry 1 Lai Quintin J · CIK 0001744326 · VP Corp Development & Strategy 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,220.8424 F1 · shares: 2016 PSUs (PP15) award vesting. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.